print   Bookmark and Share  |  RSS  |  A  A  A

ASTRO 2013


ATLANTA (Sept. 23, 2013) – The Winship Cancer Institute’s strength in radiation oncology research and translational care is evident in the 36 notable presentations by Winship members at the Annual Meeting of the American Society of Radiation Oncology (ASTRO) being held at the Georgia World Congress Center in Atlanta, Sept. 22 – 25.

Walter J. Curran, MD, executive director of the Winship Cancer Institute of Emory University, and Group Chairman of the Radiation Therapy Oncology Group (RTOG), kicked off the meeting on Sunday morning with the welcoming address. Curran says ASTRO 2013 is showcasing outstanding research by members of Winship and residents and faculty of the Emory Department of Radiation Oncology, including several important multi-center clinical trials conducted by RTOG.

“We are seeing a robust culture of clinical research emerge from the broad radiation oncology community, evidenced by the scope and breadth of science being presented at the meeting,” says Curran. “Our researchers and physicians at Winship are at the forefront of this exciting time.”

Winship leaders also guide the work of RTOG, the leading clinical research organization in radiation oncology. Deborah W. Bruner, RN, PhD, FAAN, associate director of outcomes at the Winship Cancer Institute and principal investigator of the RTOG CCOP Research Base, will lead a plenary session on an RTOG trial evaluating the feasibility of screening patients for depression in the radiation oncology clinic. She is also on a panel with Martin Sanda, MD, Winship member and chair of the Emory Department of Urology, that will look at patient-reported quality of life following radiation therapy for prostate cancer.

“I applaud ASTRO for making patient-centered care a meeting focus and the achievement of RTOG investigators who have demonstrated the important role and capability of community-based radiation oncology programs in successfully carrying out radiation therapy toxicity-reduction and quality-of-life clinical trials,” says Bruner.

Other presentations during the meeting will look at the reporting of initial trial results of new RT techniques, combined modality treatment, and symptom management.

For the full ASTRO schedule, go to:

More news about RTOG trials:

RTOG 0841: Screening for Depression in Cancer Patients Receiving Radiotherapy

RTOG 0617: Patient-Reported QOL Outcomes in Trial Evaluating Increased RT Dose for Lung Cancer

RTOG 9910: Short Course Hormonal Therapy Prior to Radiotherapy for Intermediate-RIsk Prostate Cancer Patients 

RTOG 0933: Avoidance of the Hippocampus is Shown to Preserve Memory 

Winship Contact: Catherine Williams;

Return To Previous Page